Navigation Links
Interim Analysis Supports Continuation of Cell Genesys' VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer
Date:1/14/2008

America and Europe.

The company's second Phase 3 trial, VITAL-2, is a multi-center, randomized, controlled Phase 3 clinical trial designed to evaluate the safety and efficacy of GVAX immunotherapy for prostate cancer used in combination with Taxotere chemotherapy compared to the use of Taxotere chemotherapy and prednisone in HRPC patients with metastatic disease who are symptomatic with cancer-related pain. The primary endpoint of the trial is also an improvement in survival. VITAL-2 was initiated in June 2005 and is currently enrolling patients at approximately 90 sites in North America and Europe. The company expects to complete enrollment of approximately 600 patients in the first half of 2009 and if this is achieved, to have a sufficient number of events for a pre-planned interim analysis at that time.

The U.S. Food and Drug Administration (FDA) granted Cell Genesys Special Protocol Assessments (SPAs) for both VITAL-1 and VITAL-2. The SPA is a process that allows for official FDA evaluation of a Phase 3 clinical trial and provides trial sponsors with a binding written agreement that the design and analysis of the study are adequate to support a license application submission if that study is performed according to the SPA. Cell Genesys completed the modifications requested by FDA during the review process.

About GVAX Cancer Immunotherapies

GVAX cancer immunotherapies are non patient-specific investigational therapeutics comprised of whole tumor cells that have been modified to secrete GM-CSF (granulocyte-macrophage colony stimulating factor), an immune stimulatory hormone, and then irradiated for safety. GVAX is designed to be administered through intradermal injections on an outpatient basis. To date, over 600 patients have been treated with GVAX cancer immunotherapies in Phase 1 and Phase 2 clinical trials for multiple indications, including prostate cancer, pancreatic cancer, and leukemia. The company is currently manufacturing GV
'/>"/>

SOURCE Cell Genesys, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
3. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
4. Interim Safety Data Favorable for Vicals Phase 2 Trial of DNA Vaccine Against CMV
5. Interim Phase 2 Data for Exelixis XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer
6. Leading Physicians Present Interim Results from Multi-Center Studies of VNUS ClosureFAST Catheter at VEITHsymposium
7. Grantees of the Avon Foundation Breast Cancer Prevention Research Initiative Gather in Houston to Report Interim Findings
8. Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program
9. Interim Safety Analysis Supports Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma
10. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
11. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)...  The Mesothelioma Victims Center is incredibly passionate ... the best possible compensation, and they are also extremely ... cancer caused by exposure to asbestos or their ... treatment options such as a recent possible medical breakthrough. ... Center anytime at 866-714-6466. http://MesotheliomaVictimsCenter.Com ...
(Date:5/22/2015)... , May 22, 2015   InspireMD, Inc. ... stent embolic protection systems ("EPS"), today announced that its CGuard ... lead by principle investigator Prof. Piotr Musialek , at ... Paris, France . PARADIGM, an ... R cutaneous c A roti D revascularization I ...
(Date:5/22/2015)...  In a sweeping analysis assessing the current state ... researchers conclude that there remains considerable room for ... age groups, but especially for adolescents and young adults. ... treatment, underscoring the need to address barriers to care ... type 1 patients achieve optimal metabolic control. ...
Breaking Medicine Technology:Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 2Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 3Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 4Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 5InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 2InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 3InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 4Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 2Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 3Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 4Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 5
... SAN DIEGO, Feb. 17, 2011 Orexigen® Therapeutics, Inc. (Nasdaq: ... Graham Cooper, senior vice president, Finance, CFO and treasurer. Mr. ... has decided to leave the Company for personal reasons.  He ... accepting the CFO role in 2006.  Mr. Cooper will remain ...
... Feb. 17, 2011 In celebration of the 31st Annual ... NXTM ), a leading manufacturer of innovative dialysis products, today ... System One for home hemodialysis.  The System One is the ... the FDA. "This new milestone demonstrates growing ...
Cached Medicine Technology:Orexigen® Therapeutics, Inc. Announces Upcoming Departure of Chief Financial Officer 2Orexigen® Therapeutics, Inc. Announces Upcoming Departure of Chief Financial Officer 3In Celebration of the 31st Annual Dialysis Conference, NxStage® Announces Over 5,000 Patients Using the System One™ for Home Hemodialysis 2In Celebration of the 31st Annual Dialysis Conference, NxStage® Announces Over 5,000 Patients Using the System One™ for Home Hemodialysis 3
(Date:5/24/2015)... New York, New York (PRWEB) May 24, 2015 ... of testosterone treatment lawsuits ( http://www.testosteronelawsuithub.com/ ) has ... discuss the progress of the multidistrict litigation. According ... Court, Northern District of Illinois, the Conference will ... p.m. (In re: Testosterone Replacement Therapy Product Liability ...
(Date:5/24/2015)... Medicx Media Solutions http://www.medicxmedia.com ... Jay Krihak as its head of programmatic strategy ... its expertise and leadership position in the data ... sectors. , Krihak is an experienced, award-winning agency ... led sales planning teams for mobile platform Jumptap. ...
(Date:5/23/2015)... 2015 On Saturday, May 23, 2015, over ... for Branches Florida City exactly five years to the day ... 2010. , A large fire tore through the Branches United ... 2010 in the middle of the night as neighbors, staff ... declared arson even though it is suspected that the fire ...
(Date:5/23/2015)... San Diego, CA (PRWEB) May 23, 2015 ... businesses, especially small businesses, are finding it increasingly difficult ... Those businesses which fail to provide adequate insurance for ... healthcare for businesses been such an integral part of ... provide more affordable healthcare for businesses, Online USA Doctors ...
(Date:5/23/2015)... 23, 2015 Manufacturers are now required to ... (HSPF) of 8.2. Experts in the field agree that the ... , The HSPF score is what miles per gallon is ... the unit. Although the minimum HSPF score has been raised ... an HSPF score north of 12. Indeed, the regulation was ...
Breaking Medicine News(10 mins):Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Look Ahead to June Conference in Federal Multidistrict Litigation 2Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Look Ahead to June Conference in Federal Multidistrict Litigation 3Health News:Medicx Media Solutions Expands Executive Team 2Health News:Five Years After Fire, Branches Rebuilds Playground 2Health News:Online USA Doctors Now Offers Cost-Saving Alternative Healthcare for Businesses 2Health News:Online USA Doctors Now Offers Cost-Saving Alternative Healthcare for Businesses 3Health News:Parker & Sons Welcomes the Department of Energy’s Water Heater Regulation 2
... Oct. 11 SeaView IPA, an Oxnard, CA ... P. Bangasser Memorial,Award for Quality Improvement from the ... a special Awards Ceremony at the 6th,Annual Pay-for-Performance ... The IHA is a statewide leadership group ...
... 2007 Physicians at UT Southwestern Medical Center are the first ... radioactive pellet, or seed, is implanted into a mass or suspicious ... removal. , During the procedure, a radiologist uses a needle to ... of rice, into the mass. Once lodged, surgeons use a wand ...
... to Support Amendment to Hologic,s 1999 Equity ... ... Inc.,(Nasdaq: HOLX ), a leading provider of state-of-the-art diagnostic and,digital ... independent proxy advisory service, recommends that,Hologic stockholders vote "FOR" the Company,s ...
... Brochure Outlines Step-by-Step Process and Provides Sample Appeal,Letter, ... many seniors peace of mind that they will have,access ... individual,plan rules, the medicine that,s prescribed by the doctor ... but they need,to know what they can do about ...
... MEMPHIS, Tenn., Oct. 11 Baptist Memorial Health ... the University of Memphis,today, bringing its recent total ... million. Last month, Baptist contributed $1 million ... to Southwest Tennessee Community,College,s nursing, natural sciences and ...
... allows hospital pharmacies to accurately manage costs and ... ... 11 Omnicell, Inc.,(Nasdaq: OMCL ) a leading provider of ... efficiency, today,announced the Omnicell WorkflowRx 5.0 central pharmacy automation solution.,With its ...
Cached Medicine News:Health News:MED3OOO Client Wins IHA Pay-for-Performance Award 2Health News:MED3OOO Client Wins IHA Pay-for-Performance Award 3Health News:New 'seed' therapy helps pinpoint breast tumors with more accuracy 2Health News:ISS Recommends Hologic Stockholders Vote 'FOR' Merger With Cytyc 2Health News:ISS Recommends Hologic Stockholders Vote 'FOR' Merger With Cytyc 3Health News:ISS Recommends Hologic Stockholders Vote 'FOR' Merger With Cytyc 4Health News:New Resource Explains What Seniors Can Do if Medicare Denies Coverage of Their Medicines 2Health News:Baptist Memorial Health Care Donates More Than $3 Million to Tennessee Universities and Colleges 2Health News:Omnicell Introduces the Next Generation Central Pharmacy Automation Solution 2Health News:Omnicell Introduces the Next Generation Central Pharmacy Automation Solution 3
For the qualitative detection of human Chorionic Gonadotrophin (HCG) in urine or urine and serum specimens...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
Medicine Products: